Bleakley Financial Group LLC acquired a new position in PetMed Express, Inc. (NASDAQ:PETS – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 75,719 shares of the company’s stock, valued at approximately $279,000. Bleakley Financial Group LLC owned 0.37% of PetMed Express as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also added to or reduced their stakes in the stock. Point72 DIFC Ltd bought a new stake in shares of PetMed Express in the second quarter valued at approximately $34,000. Oak Thistle LLC bought a new stake in shares of PetMed Express in the first quarter valued at approximately $50,000. Marshall Wace LLP bought a new stake in shares of PetMed Express in the second quarter valued at approximately $46,000. SG Americas Securities LLC bought a new stake in shares of PetMed Express in the second quarter valued at approximately $46,000. Finally, Pinnacle Wealth Planning Services Inc. bought a new stake in shares of PetMed Express in the first quarter valued at approximately $61,000. Institutional investors own 73.33% of the company’s stock.
PetMed Express Trading Down 4.9 %
PetMed Express stock opened at $3.90 on Thursday. The firm’s 50 day simple moving average is $3.56 and its 200 day simple moving average is $3.88. The firm has a market capitalization of $80.37 million, a PE ratio of -10.00 and a beta of 0.71. PetMed Express, Inc. has a 1-year low of $2.90 and a 1-year high of $10.53.
Insiders Place Their Bets
In related news, major shareholder Nina Capital Holdings Inc. purchased 12,500 shares of the business’s stock in a transaction on Monday, September 9th. The stock was acquired at an average price of $3.34 per share, with a total value of $41,750.00. Following the purchase, the insider now directly owns 2,078,000 shares in the company, valued at approximately $6,940,520. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.10% of the company’s stock.
Wall Street Analysts Forecast Growth
Separately, Lake Street Capital reaffirmed a “hold” rating and set a $3.50 target price (down previously from $7.00) on shares of PetMed Express in a report on Wednesday, August 7th.
Read Our Latest Research Report on PetMed Express
PetMed Express Company Profile
PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.
Read More
- Five stocks we like better than PetMed Express
- How to Invest in Biotech Stocks
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Trading Stocks: RSI and Why it’s Useful
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.